GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development
June 13 2022 - 9:00AM
via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company specializing in developing human vaccines and
cancer immunotherapies, today announced the appointment of John W.
Sharkey, PhD to serve as Vice President, Business Development.
Dr. Sharkey brings over 30 years of experience in
the pharmaceutical and medical device industry, with specific
expertise in executive management, business development,
pharmaceutical and medical device development, regulatory affairs,
manufacturing and business operations covering multiple therapeutic
segments. Over his career, Dr. Sharkey has been a key contributor
to the development, acquisition, or divestment of multiple products
with annual revenues ranging from $5 million to more than $2
billion.
Prior to his current appointment as Vice
President, Business Development for GeoVax, Dr. Sharkey served as
the Company’s Head of Business Development on a part-time
consulting basis and led the successful completion of two
transformational transactions which propelled the company into
Phase 2 programs in the areas of COVID-19 and
Immuno-Oncology.
In 2010, Dr. Sharkey founded Cogas Consulting,
LLC, a boutique consultancy providing executive management,
technical development, regulatory and business development services
to small and mid-size pharma and medical device companies. He has
also assisted several companies in their financing activities. As
CEO of Largent Health, LLC, he oversaw the development strategy for
three 510(k) medical devices incorporating a proprietary
antimicrobial technology, eventually leading to the registration
and commercial launch of the first FDA-cleared dental cavity
cleanser with antimicrobial claims. Previously, he held senior
executive positions within both Novartis Pharmaceuticals
Corporation and Shionogi Pharmaceuticals, Inc. and engaged in
several notable partnering transactions including Novartis’
acquisition of ex-U.S. rights for Lucentis® and global rights for
Focalin® and Focalin® XR as well as Shionogi’s acquisition of
global rights for Osphena®.
Dr. Sharkey holds a Ph.D. in Chemistry from the
University of Buffalo and a B.S. in Chemistry from the State
University of New York at Oneonta.
David Dodd, GeoVax President and CEO, commented,
“John’s addition to our team represents an important step forward
in the strengthening of GeoVax’s organizational and operational
resources. He has already made important contributions to GeoVax’s
progress in his consulting role and we are delighted that he has
agreed to join us on a full-time basis. We are excited to
leverage the wealth of knowledge, expertise, and insights he brings
and we look forward to his further contributions to the growth and
development of the Company in support of our strategic corporate
growth plans and objectives.”
About GeoVaxGeoVax Labs, Inc. is a
clinical-stage biotechnology company developing human vaccines and
immunotherapies against infectious diseases and cancer using novel
proprietary platforms. GeoVax’s product pipeline includes two
ongoing Phase 2 clinical trials of GEO-CM04S1 (formerly COH04S1)
for COVID-19 as a universal booster vaccine to mRNA vaccines
authorized by the U.S. Food and Drug Administration (FDA) and as a
primary vaccine for use in immunocompromised patients. In addition
to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02 as a
pan-coronavirus vaccine. The Company is also conducting a Phase 1/2
clinical trial of Gedeptin® for treatment of head and neck cancer.
Gedeptin® has been granted orphan drug status by the FDA.
Additional research and development programs include preventive
vaccines against Zika Virus, hemorrhagic fever viruses (Ebola,
Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies
for multiple solid tumors. The Company’s portfolio of wholly owned,
co-owned, and in-licensed intellectual property stands at over 70
granted or pending patent applications spread over 20 patent
families.
For additional information about GeoVax, visit our
website: www.geovax.com.
GeoVax Labs,
Inc.678-384-7220investor@geovax.com
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Sep 2024 to Oct 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Oct 2023 to Oct 2024